13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858198
Total reported value
$136.2M
$136.2M
32 檔
41.3%
As reported in its official Q1 2026 Form 13F filing, KVP Capital Advisors, LP's tracked investment portfolio stood at $136.2M with 32 total positions.
In Q1 2026, KVP Capital Advisors, LP displayed an active expansion posture, initiating 9 new positions and adding to 1 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 17.32% | -17.32% | EXIT | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 10.32% | +0.22% | — | |
| 3 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 5.58% | +1.70% | — | |
| 4 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 4.57% | -2.41% | — | |
| 5 | STRO | Sutro Biopharma Inc | Stock-Other | 4.22% | +1.30% | — | |
| 6 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 4.17% | +0.60% | — | |
| 7 | ERAS | Erasca Inc | Stock-Other | 4.11% | +2.01% | — | |
| 8 | TRVI | Trevi Therapeutics Inc | Stock-Other | 3.69% | +1.98% | — | |
| 9 | TNGX | Tango Therapeutics Inc | Stock-Other | 3.60% | +1.68% | — | |
| 10 | INSM | Insmed Inc | Stock-Healthcare | 3.48% | -1.25% | — | |
| 11 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 3.13% | +0.84% | — | |
| 12 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.92% | -2.92% | EXIT | |
| 13 | IRON | Disc Medicine Inc | Stock-Other | 2.78% | +0.35% | — | |
| 14 | MBX | Mbx Biosciences Inc | Stock-Other | 2.71% | +2.21% | — | |
| 15 | SVRA | Savara Inc | Stock-Other | 2.47% | +0.27% | — | |
| 16 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.10% | -0.21% | — | |
| 17 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.02% | -0.39% | — | |
| 18 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.98% | +0.20% | — | |
| 19 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.98% | -0.74% | — | |
| 20 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.90% | +0.26% | — | |
| 21 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.83% | -0.14% | — | |
| 22 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.73% | -0.09% | — | |
| 23 | ✓ | Zura Bio LTD | Stock-Other | 1.66% | -0.04% | — | |
| 24 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.65% | +0.17% | — | |
| 25 | IMMX | Immix Biopharma Inc | Stock-Other | 1.57% | +0.17% | — | |
| 26 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.49% | -1.49% | EXIT | |
| 27 | NKTR | Nektar Therapeutics | Stock-Other | 1.45% | -0.07% | — | |
| 28 | CABA | Cabaletta Bio Inc | Stock-Other | 1.02% | +0.13% | — | |
| 29 | ACHV | Achieve Life Sciences Inc | Stock-Other | 1.02% | +1.20% | — | |
| 30 | VERA | Vera Therapeutics Inc | Stock-Other | 0.98% | +0.05% | — | |
| 31 | CELC | Celcuity Inc | Stock-Other | 0.34% | -0.03% | — | |
| 32 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.22% | +0.02% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | +0.8% | +46.18% | Add |
| 2 | WHWK | Whitehawk Therapeutics Inc | +0.5% | — | Unchanged |
| 3 | IMMX | Immix Biopharma Inc | +0.4% | — | Unchanged |
| 4 | NKTR | Nektar Therapeutics | +0.4% | — | Unchanged |
| 5 | 430 | Terns Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 6 | CABA | Cabaletta Bio Inc | -0.1% | — | Unchanged |
| 7 | CELC | Celcuity Inc | -0.1% | — | Unchanged |
| 8 | EWTX | Edgewise Therapeutics Inc | -0.1% | — | Unchanged |
| 9 | VYNE | Vyne Therapeutics Inc | -0.1% | — | Unchanged |
| 10 | UTHR | United Therapeutics CORP | -0.1% | — | Unchanged |
| 11 | SRRK | Scholar Rock Holding CORP | -0.3% | — | Unchanged |
| 12 | PTGX | Protagonist Therapeutics Inc | -0.3% | — | Unchanged |
| 13 | VERA | Vera Therapeutics Inc | -0.6% | — | Unchanged |
| 14 | MBX | Mbx Biosciences Inc | -1% | — | Unchanged |
| 15 | SVRA | Savara Inc | -1.1% | — | Unchanged |
| 16 | SLNOEUR | Soleno Therapeutics Inc | -1.2% | — | Unchanged |
| 17 | ACHV | Achieve Life Sciences Inc | -1.2% | — | Unchanged |
| 18 | INSM | Insmed Inc | -1.3% | — | Unchanged |
| 19 | TRVI | Trevi Therapeutics Inc | -1.3% | — | Unchanged |
| 20 | TVTX | Travere Therapeutics Inc | -1.3% | — | Unchanged |
| 21 | IRON | Disc Medicine Inc | -1.7% | — | Unchanged |
| 22 | AXSM | Axsome Therapeutics Inc | -1.8% | — | Unchanged |
| 23 | PRAX | Praxis Precision Medicines I | -1.9% | — | Unchanged |
| 24 | STRO | Sutro Biopharma Inc | — | NEW | New buy |
| 25 | ERAS | Erasca Inc | — | NEW | New buy |
| 26 | ✓ | Jazz Pharmaceuticals PLC | — | EXIT | Sold out |
| 27 | TNGX | Tango Therapeutics Inc | — | NEW | New buy |
| 28 | JAZZ | Jazz Pharmaceuticals plc | — | EXIT | Sold out |
| 29 | IDYA | Ideaya Biosciences Inc | — | NEW | New buy |
| 30 | CMPX | Compass Therapeutics Inc | — | NEW | New buy |
| 31 | OCUL | Ocular Therapeutix Inc | — | NEW | New buy |
| 32 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 33 | DRUG | Bright Minds Biosciences Inc | — | NEW | New buy |
| 34 | ✓ | Zura Bio LTD | — | NEW | New buy |
| 35 | ✓ | Fulcrum Therapeutics Inc | — | EXIT | Sold out |
| 36 | FULC | Fulcrum Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, KVP Capital Advisors, LP reported a total U.S. public equity portfolio value of $136.2M across 32 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 430, PRAX, WHWK) accounted for 41.3% of total reported equity market value during Q1 2026.
Top New Position Initiated
STRO
市值: $5.6M
Top Position Liquidated / Trimmed
JAZZ PHARMACEUTICALS PLC
前期市值: $5.3M
During Q1 2026, KVP Capital Advisors, LP's top holdings by market value included 430 (17.3%)、PRAX (10.3%)、WHWK (5.6%). The largest single position, 430, represented 17.3% of total portfolio value.
In Q1 2026, KVP Capital Advisors, LP made 14 total portfolio adjustments, initiating 9 new buys, adding to 1 positions, trimming 0 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.